Business Wire

SES’s C-band Satellite Successfully Launched Onboard SpaceX Rocket

Share

SES announced today that the SES-22 satellite was successfully launched into space onboard a SpaceX Falcon 9 rocket from SpaceX’s Space Launch Complex 40 at Cape Canaveral Space Force Station in Florida, United States, at 5:04 pm local time.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005978/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

SES’s C-band Satellite Successfully Launched Onboard SpaceX Rocket (Photo: Business Wire)

The first of SES’s C-band satellites dedicated to freeing up the lower 300 MHz of C-band spectrum is built by Thales Alenia Space, and will operate in the 135 degrees West orbital slot. It will deliver TV and radio to millions of American homes and provide other critical data transmission services. SES-22 is expected to start operations by early August 2022.

The launch of SES-22 is part of a broader Federal Communications Commission (FCC) program to clear a portion of C-band spectrum to enable wireless operators to deploy 5G services across the contiguous US (CONUS). In response to a mandate from the FCC, satellite operators such as SES are required to transition their existing services from the lower 300 MHz to the upper 200 MHz of C-band spectrum to make room for 5G.

To meet the FCC’s accelerated deadline of clearing C-band spectrum across the US by December 2023 while maintaining uninterrupted services, SES will launch five satellites – SES-18, SES-19, SES-20, SES-21 and SES-22 in 2022.

“We are thrilled with the successful launch of SES-22, thanks to our partners at Thales Alenia Space and SpaceX,” said Steve Collar, CEO of SES. “The launch of SES-22, together with other upcoming C-band satellite launches scheduled this year, will enable us to continue providing the high-quality services that our customers have been accustomed to over the last several decades, while freeing up spectrum that will enable the US to rapidly unlock the promise of 5G.”

“The successful launch of SES 22 is the result of our long-standing and fruitful collaboration with SES,” said Hervé Derrey, President and CEO of Thales Alenia Space. “This achievement reflects the robustness and flight-proven heritage of our Spacebus 4000 B2 platform combined with our ability to timely and quickly deliver SES-22, two key elements leading to the decision of SES working with us to replace its existing C-Band fleet.”

The SES-22 spacecraft had a fast on-ground delivery time as satellite manufacturer Thales Alenia Space shipped it only 22 months after it was ordered. SES-22 is the seventh SES satellite launched by SpaceX over the last 10 years.

More information of SES-22 and other C-band satellites available here.

Follow SES on:
TwitterFacebookYouTubeLinkedInInstagram
Read our Blogs >
Visit the Media Gallery >

About SES

SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries ~8,200 channels and has an unparalleled reach of 366 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com.

Follow Thales Alenia Space on:
LinkedIn | Twitter | Facebook | YouTube | Instagram

About Thales Alenia Space

Drawing on over 40 years of experience and a unique combination of skills, expertise and cultures, Thales Alenia Space delivers cost-effective solutions for telecommunications, navigation, Earth observation, environmental management, exploration, science and orbital infrastructures. Governments and private industry alike count on Thales Alenia Space to design satellite-based systems that provide anytime, anywhere connections and positioning, monitor our planet, enhance management of its resources, and explore our Solar System and beyond. Thales Alenia Space sees space as a new horizon, helping to build a better, more sustainable life on Earth. A joint venture between Thales (67%) and Leonardo (33%), Thales Alenia Space also teams up with Telespazio to form the parent companies’ Space Alliance, which offers a complete range of services. Thales Alenia Space posted consolidated revenues of approximately 2.15 billion euros in 2021 and has around 8,900 employees in 10 countries with 17 sites in Europe and a plant in the US.

www.thalesaleniaspace.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Suzanne Ong
External Communications
+352 710 725 500
suzanne.ong@ses.com

Sandrine Bielecki
Thales Alenia Space Press
+33 (0)4 92 92 70 94
sandrine.bielecki@thalesaleniaspace.com

Catherine des Arcis
Thales Alenia Space Press
+33 (0)4 92 92 72 82
catherine.des-arcis@thalesaleniaspace.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF Unveils Nourish Innovation Lab in Union Beach, New Jersey19.8.2022 12:55:00 CEST | Press release

IFF (NYSE:IFF) today announced the opening of its new Nourish Innovation Lab at the company’s Union Beach, New Jersey research and development center. In the state-of-the-art lab, scientists—including flavorists and food designers—will leverage tools, technologies and ingredient expertise to offer customers full product design, driving growth in the global food and beverage markets by fast forwarding innovation. “This new facility is a testament to how we pioneer innovation and drive speed to market and accessibility to our customers,” said Nicolas Mirzayantz, president of Nourish, IFF. “We will nurture an innovation project from concept to kitchen table, under one roof. Using our scientific knowhow, application excellence and full portfolio of ingredients, we’ll improve the taste and nutrition profiles of next-generation food and beverages. With our new culinary kitchen, we’re enabling technology focused on the consumer-eating experience, taking food development out of the traditional

PUMA Ambassador and European Champion Gianmarco Tamberi Talks “Only See Great”19.8.2022 11:52:00 CEST | Press release

Six years after his first gold medal, Tamberi takes back the European title and speaks about his motivation to keep performing at the highest level in a video interview with sports company PUMA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220819005125/en/ Six years after his first gold medal, Tamberi takes back the European title and speaks about his motivation to keep performing at the highest level in a video interview with sports company PUMA. (Photo: Business Wire) With the ‘Only See Great’ campaign, PUMA explores the career path of its brand ambassadors, as they talk about their own pursuit of greatness, listening to their hearts, and finding a vision that no one else can see. In the interview, Gianmarco talks about his very first successes and extraordinary performance at the Olympic Games in Tokyo. “That feeling that I had that day, that happiness I couldn’t even imagine that could exist. It’s something that was co

Kyowa Kirin Receives European Commission Approval for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)19.8.2022 10:30:00 CEST | Press release

Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the European Commission (EC) approved CRYSVITA® (burosumab) for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed in the EU for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with fewer than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with progressive and debilitating musculoskeletal deficits,6,7 ultimately having a detr

Kapruvia ® approved in Switzerland with additional regulatory decisions expected in H2 202219.8.2022 07:00:00 CEST | Press release

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia® will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients. Swissmedic approval for Kapruvia® follows approvals by the U.S. Food and Drug Administration, by the European Medicines Agency, by the UK Medicines and Healthcare products Regulatory Agency, as well as by Health Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005552/en/ “The approval of Kapruvia® in Switzerland is the next step on our journey to bring this breakthrough treatment to hemodialysis patients living with CKD-associated pruritus around the world,” said Dr. Klaus Henning Jensen, Chief Medical Officer of CSL Vifor. “There is a

European Commission Approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer19.8.2022 04:47:00 CEST | Press release

Celltrion Healthcare announced today that the European Commission (EC) has approved Vegzelma™ (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin®, for the treatment of metastatic breast cancer, non-small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer and cervical cancer. “The European Commission’s approval of Vegzelma™ will increase access to treatment for patients living with certain types of cancer at an affordable price,” said Kevin Byoung Seo Choi, Senior Vice President and Head of Marketing Division at Celltrion Healthcare. “With proven similarities in efficacy and safety compared to the reference product Avastin®, Vegzelma™ will be available to treat some of the most commonly diagnosed cancers, which collectively affect hundreds of thousands of European patients each year.” The EC approval of Vegzelma™ follows the recommendation for marketing authorisation issued by the Committee for Medi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom